PPLPHARMA Piramal Pharma Q4 FY25 results (Jan–Mar 2025) and concall
Piramal Pharma delivered a strong finish to FY25, hitting the $1 billion revenue milestone and significantly improving profitability. However, management proactively flagged a transition year in FY26, where revenue growth will slow to mid-single digits as a major CDMO customer normalizes inventory following a blockbuster launch. The company remains bullish on its long-term FY30 targets, supported by capacity expansions in the US and a shift toward high-margin innovation-led CDMO work.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|
| Revenue | 2,242 | 2,204 | 2,754 |
| EBITDA | 342 | 338 | 561 |
| Net profit | 23 | 4 | 154 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
